Vol. 68, No. 9
JOURNAL OF VIROLOGY, Sept. 1994, p. 6006-6013
0022-538X/94/$04.00 + 0
Copyright ©D 1994, American Society for Microbiology
Cryptic Nature of Envelope V3 Region Epitopes Protects
Primary Monocytotropic Human Immunodeficiency
Virus Type 1 from Antibody Neutralization
DUMITH CHEQUER BOU-HABIB,' GREGORY RODERIQUEZ,' TAMAS ORAVECZ,
PHILLIP W. BERMAN,2 PAOLO LUSSO,3 AND MICHAEL A. NORCROSS'*
Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration,' and
Laboratory of Tumor Cell Biology, National Cancer Institute,3 Bethesda, Maryland 20892, and Department of
Immunology, Genentech, Inc., South San Francisco, Califomia 940802
Received 6 April 1994/Accepted 14 June 1994
molecular structure of the third variable domain (V3 loop) of
the virus envelope protein, gpl20 (13, 20, 30). Viral genetic
Human immunodeficiency virus type 1 (HIV-1), the etiologic agent of AIDS (3, 15), has been cultivated in primary
CD4+ T cells, mononuclear phagocytes, and tumor cell lines.
Various HIV-1 phenotypes can be distinguished on the basis of
properties of the virus in culture. In general, HIV-1 isolates
that preferentially infect CD4+ T-cell lines are able to induce
formation of syncytia and have been referred to as syncytiuminducing (SI) viruses (13, 22, 39). T-cell-tropic isolates grow
with high replication rates (38) and exhibit high sensitivity to
inactivation by soluble CD4 (sCD4) (10, 26), and their detection in clinical samples is correlated with the decline in CD4+
T-cell number and progressive loss of T-cell immune function
(17, 33-35, 39). In contrast, monocytotropic (MT) HIV-1
isolates usually do not infect CD4+ T-cell lines or induce
formation of multinucleated giant cells in vitro; they therefore
have been referred to as non-SI viruses (13, 22, 39). Relative to
T-cell-tropic isolates of HIV-1, MT viruses grow with low
replication rates (39), are resistant to inactivation by sCD4 (10,
26), and are the virus types more frequently associated with in
vivo transmission (45) and with the asymptomatic clinical
status of HIV-1-infected individuals (17, 33-35, 39). Recently,
several investigators have presented preliminary evidence that
primary/MT isolates (field isolates) are remarkably resistant to
antibody neutralization using hyperimmune sera from vaccinees or HIV-1-infected individuals (9).
A close correlation exists between HIV-1 phenotype and the
constructs in which the V3 structure was altered showed
changes in cell tropism and replication rate (6, 8, 11, 12). The
V3 loop also represents the dominant antibody neutralization
site of gpl20 (for a review, see reference 44), and its sequence
variability is important in determining virus susceptibility to
neutralizing antibodies (21). Thus, the V3 loop has been
termed the HIV-1 principal neutralizing domain.
In this report, we present biological, immunological, and
partial genetic data directly comparing a prototype MT isolate
of HIV-1, JR-CSF (7), with a T-cell-tropic variant selected in
tissue culture. Antibody neutralization assays revealed a
marked shift, from an antibody-resistant phenotype characteristic of the MT viruses to an antibody-sensitive T-cell-tropic
phenotype. Antibody resistance of the primary isolate was
related to reduced exposure of immunodominant V3 domain
epitopes.
MATERUILS AND METHODS
Reagents, viruses, and antisera. Mouse monoclonal antibodies (MAbs) 50.1 and 59.1 (43), directed to the V3 loop of
the MN strain of HIV-1 (epitopes RIHIG and GPGRAF,
respectively), were generously donated by A. Profy (Repligen,
Cambridge, Mass.). The mouse V3 domain-specific MAbs
1026 and 1034 were raised against gpl20 of HIV-1 MN and
cross-react with recombinant JR-CSF gpl20 as well as with the
consensus V3 peptide (reference 29 and unpublished results).
Peptide mapping and the sensitivity of antibody binding to
protease-mediated cleavage between arginine and alanine in
the GPGRAF sequence indicated that both MAb 1026 and
*
Corresponding author. Mailing address: Division of Hematologic
Products, Center for Biologics Evaluation and Research, Food and
Drug Administration, NIH, Building 29A, Room 3B10, 8800 Rockville
Pike, HFM-541, Bethesda, MD 20892. Phone: (301) 496-3110. Fax:
(301) 480-3256.
6006
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
Characterization of biological and immunological properties of human immunodeficiency virus type 1
(HIV-1) is critical to developing effective therapies and vaccines for AIDS. With the use of a novel CD4+ T-cell
line (PM-1) permissive to infection by both monocytotropic (MT) and T-cell-tropic virus types, we present a
comparative analysis of the immunological properties of a prototypic primary MT isolate of HIV-1 strain
JR-CSF (MT-CSF) with those of a T-cell-tropic variant (T-CSF) of the same virus, which emerged
spontaneously in vitro. The parental MT-CSF infected only PM-1 cells and was markedly resistant to
neutralization by sera from HIV-1-infected individuals, rabbit antiserum to recombinant MT-CSF gpl20, and
anti-V3 monoclonal antibodies. The T-CSF variant infected a variety of CD4+ T-cell lines, contained positively
charged amino acid substitutions in the gpl20 V3 region, and was highly sensitive to antibody neutralization.
Neutralization and antibody staining of T-CSF-expressing cells were significantly inhibited by HIV-1 V3
peptides; in contrast, the MT strain showed only weak V3-specific binding of polyclonal and monoclonal
antibodies. Exposure of PM-1 cells to a mixture of both viruses in the presence of human anti-HIV-1
neutralizing antiserum resulted in infection with only MT-CSF. These results demonstrate that although the
V3 region of MT viruses is immunogenic, the target epitopes in the V3 principal neutralizing domain on the
membrane form of the MT envelope appear to be cryptic or hidden from blocking antibodies.
VOL. 68, 1994
CRYPTIC V3 REGION PROTECTS HIV-1 FROM NEUTRALIZATION
The percentages of CPE and of inhibition of CPE were
calculated by using the following equations:
% CPE
=
1-
% inhibition CPE =
(CPE\
I x 100
total
Ab
-
CPE
x 100
total CPE
where OD values were from wells containing HIV-1-infected
cells and uninfected T-cell lines (CPE), HIV-1-infected cells
and T-cell lines in the presence of MAbs SIM-2 and SIM-4
(total), and HIV-1-infected cells and T-cell lines in the presence of anti-HIV-1 polyclonal sera or MAbs (Ab). Values for
CPE and the percentage of syncytium-forming cells correlated
in each experiment. For peptide blocking experiments, V3 loop
peptides (10,ug/ml) were incubated for 1 h at 37°C with 100 RI
of diluted neutralizing antiserum before the addition of infected cells. For neutralization assays with infectious cell-free
supernatants, 200 tissue culture infectious doses (defined here
as the endpoint in a twofold serial dilution of an infectious
supernatant which is positive for syncytium formation in PM-1
cells after 6 days) of virus were incubated for 1 h at 37°C with
antiserum. Uninfected cells (2 x 104 per well) were added, and
the plates were incubated for 6 to 7 days. CPE was measured
as described above. Viral p24 antigen in culture supernatants
was quantitated with an immune complex dissociation kit
(ICD-Prep; Coulter) followed by an HIV-1 p24 antigen capture assay (Coulter).
DNA sequencing of the HIV-1 JR-CSF env gene. Lysates of
the cell lines stably infected with HIV-1 JR-CSF were subjected to PCR amplification with the primers 5'-CCA ACC
-
CAC AAG AAG TAG TAT TGG-3' and 5'-ACC ATC TCT
TGT TAA TAG CAG CCC-3', which generate a product from
nucleotides 6471 to 7615 of the env gene (4). DNA sequence
was determined with a set of sequencing primers derived from
the PCR primers and from conserved regions of the envelope
(27). Sequencing was performed on an Applied Biosystems
370A DNA sequencer. The sequences of the additional primers were 5'-GGG ATC AAA GCC TAA AGC CAT G-3',
5'-TAC AAT GTA CAC ATG GAA TT-3', 5'-TGG CAG
TCT AGC AGA AGA A-3', 5'-GAA TTT TC TAC TGT
AAT TC-3', 5'-GAA TTA CAG TAG AAA AAT TCC CCT
CC-3', 5'-TTC TTC TGC TAG ACT GCC A-3', and 5'-AAT
TCC ATG TGT ACA TTG TA-3'.
RESULTS
MT strains of HIV-1 characteristically do not replicate in
T-cell lines. Propagation of these isolates in vitro is
usually accomplished through viral passage in normal monocytes or peripheral blood lymphocytes. In this study, in order to
directly compare virus isolates, we used the CD4+ T-cell line
PM-1 for continuous replication of the molecularly cloned MT
isolate JR-CSF. This cell line is permissive to infection with
both MT (for example, JR-FL and Ba-L) and T-cell-tropic (for
example, IIIB and MN) HIV-1 phenotypes (23). After chronic
infection with the primary JR-CSF isolate (MT-CSF), this cell
line expresses large amounts of gpl20 and is able to fuse with
uninfected PM-1 cells, forming multinucleated cells.
After 5 months of continuous culture in PM-1 cells, HIV-1
JR-CSF broadened in cell tropism, from a PM-1 cell-restricted
virus to one capable of infecting a variety of CD4+ tumor cell
lines, a biological property characteristic of T-cell-tropic isolates. To establish a cell line chronically infected only with
CD4+
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
MAb 1034 recognize the tip of the V3 domain (data not
shown). Mouse MAbs SIM-2 and SIM-3, directed to CD4 (31),
and the cell-free supernatants containing HIV-1 JR-CSF (7) or
the T-cell-tropic HIV-1 MN strain (37) were obtained from the
AIDS Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (contributions of James Hildreth, Irvin Chen, and Robert Gallo, respectively). The rabbit antiserum PB69 was generated against
HIV-1 JR-CSF recombinant gpi20 (28), which is identical in
sequence to MT-CSF used in this study. Serum samples were
obtained from HIV-1-infected individuals and from healthy
donors, inactivated at 56°C for 30 min, and stored at -70°C
until use.
Cells. The CD4+ T-cell lines PM-1, H9 (32), MT-2 (18), and
SUP-Ti (38) were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 U/ml), streptomycin (100 ,ug/ml), 2 mM glutamine,
and 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid (HEPES).
Virus infections. The primary JR-CSF isolate (MT-CSF)
and the T-cell-tropic variant (T-CSF) infect and persistently
replicate in PM-1 cells, which are permissive to infection by
and replication of primary isolates and laboratory-adapted
strains of HIV-1 (23). PM-1 and H9 cells were infected by
mixing cells with virus suspensions as previously described (7).
Newly infected cells usually formed multinucleated syncytia
after 3 to 4 days in culture, developing into chronically infected
cell lines by 2 weeks.
Indirect immunofluorescence. Cells chronically infected
with HIV-1 (2 x 105) were incubated with antiserum from
HIV-1-infected individuals (1:100 dilution) or mouse MAbs (5
,ug/ml) for 30 min at room temperature in 100 ,ul of culture
medium. Cells were washed twice and then incubated with
fluorescein isothiocyanate (FITC)-conjugated goat F(Ab')2
fragments to human immunoglobulins A, G, and M (Cappel)
or FITC-conjugated goat F(Ab')2 to mouse immunoglobulin G
(Cappel) for 30 min at room temperature. Cells were washed,
fixed with 1% paraformaldehyde, and analyzed with a FACScan fluorescence-activated flow cytometer (Becton-Dickinson). The effect of V3 loop peptides on human antibody
binding was investigated by incubating antiserum with synthetic peptides (50 ,ug/ml) for 1 h before cell staining. Peptide
sequences were as follows: consensus peptide, CGRPNNNTRK
SIHIGPGRAFYlT?GEIIGDIRQAHC; HIV-1 MN peptide,
CNKRKRIHIGPGRAFYTTKN; and HIV-1 strain RF peptide,
CNTRKSITKGPGRVIYATGQ (American Bio-Technologies).
A peptide from the third domain of the CD4 molecule (CD4B;
donated by F. Robey, National Institute of Dental Research),
with the sequence TFDLKNKEVSVKRVTQDPKL, was used as
a control.
Syncytium formation and neutralization assays. Infected
PM-1 cells (104 per well) were incubated for 1 h at 37°C under
5% CO2 in a flat-bottom microtiter plate with 100 RI of culture
medium (without phenol red) in the absence or presence of
human antiserum to HIV-1, rabbit PB69 antiserum, or mouse
MAb 1026 or 1034 at the indicated concentrations. Target cells
(5 x 104 in 100 RI) were then added, and 24 h later, the wells
were evaluated for the presence of multinucleated giant cells.
Cytopathic effect (CPE) was determined colorimetrically after
72 h, by the addition of 50 RI of 2,3-bis[2-methoxy-4-nitro-5sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT; Sigma)
and measurement of optical density (OD) at 450 nm as
previously described (36). The CPE was calculated on the basis
of the OD measured in wells in which the anti-CD4 MAbs
SIM-2 and SIM-4 were added at saturating concentrations to
block syncytium formation and preserve 100% cell viability.
6007
6008
BOU-HABIB ET AL.
J. VIROL.
TABLE 1. Amino acid sequences of the gpl2O V3 domains
of MT-CSF, T-CSF, and MN'
100
Strain
Sequence"
MT-CSF... S N N T R K S . I H I G P G R A F Y T T G E
T-CSF ... N N N K R K R I I H I G P G R A F Y K T G E
NYNKRKR
MN ...
IHIGPGRAFYTTKN
w
a.
o
a Sequences were aligned according to Myers et al. (27) from amino acid
position 298 of MT-CSF. The MN sequence is shown for comparison. T-CSF
contains an insertion (I), and the dots were placed for correct alignment.
40
20
0
PM-1 T-CSF
FIG. 1. Tropism of MT-CSF and T-CSF HIV-1 isolates. PM-1 cells
infected with MT-CSF or T-CSF (104 per well) were incubated with
PM-1, MT-2, H9, or SUP-Ti cells (5 x 104 per well), and CPE was
evaluated colorimetrically after 72 h as described in Materials and
Methods. Data are means ± standard errors for a representative
experiment. The tropism of HIV-1 MN (MN-infected H9 cells) was
also determined for comparison.
T-cell-tropic virus, we infected H9 cells with culture supernatants containing the T-cell-tropic variant (T-CSF) and then
transferred the resulting virus back to PM-1 cells. The resultant T-CSF-infected PM-1 cells were then assayed with several
T-cell lines for syncytium formation and CPE to determine the
cell tropism of the virus. T-CSF induced syncytia in and was
cytopathic to PM-1, MT-2, H9, and SUP-Ti cells, whereas the
MT-CSF parental strain formed syncytia and was cytopathic
only in PM-1 cells (Fig. 1). The two virus isolates showed
similar replication rates in PM-1 cells (data not shown).
T-cell-tropic viruses contain characteristic positively charged
amino acids in the V3 region (6, 8, 11-13). We therefore
determined the DNA sequence that spans the gpi20 V3 region
from both variant and parental viruses. Several differences
were apparent in the V3 region between the MT-CSF and
T-CSF isolates (Table 1): Ser-298, Thr-301, Ser-304, and
Thr-315 in MT-CSF were replaced by Asn, Lys, Arg, and Lys,
respectively, in T-CSF. The Thr-301-to-Lys substitution disrupts the glycosylation recognition sequence (NXT) and
should eliminate N-linked carbohydrate at this site. T-CSF also
contained an Ile insertion between positions 304 and 305 of
MT-CSF. Thus, the V3 domain of T-CSF contained three
more positive residues (Lys, Arg, and Lys) than the parental
MT V3 domain, and these changes occurred at positions that
have been shown to be critical for development of the T-celltropic or SI phenotype (6, 8, 11-13).
Amino acid substitutions in the V3 region or in the other
envelope sites may alter the conformation of the envelope,
possibly affecting its exposure and antigenicity. To examine the
relative exposure of the V3 loops of MT-CSF and T-CSF, we
measured the binding of MAbs directed to the gpi20 V3 loop
FIG. 2. (A) Polyclonal human antibody and monoclonal anti-V3 antibody binding to PM-1 cells chronically infected with MT-CSF or T-CSF.
Infected cell lines were incubated with human antiserum to HIV-1 or a mouse MAb (50.1, 59.1, 1034, or 1026) to V3, washed, and then incubated
with appropriate FITC-conjugated secondary antibodies. After fixation, the cells were analyzed with a FACScan flow cytometer. (B) Effect of prior
treatment of human anti-HIV-1 antiserum with V3 peptides on antibody binding to PM-1 cells infected with MT-CSF or T-CSF. Human antiserum
to HIV-1 was incubated with a peptide (50 ,ug/ml) corresponding to the consensus (Con), MN, or RF V3 sequence or with a control peptide
corresponding to the third domain of CD4 (CD4B) before exposure to infected cells and indirect immunofluorescence assay.
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
PM-1 MT-CSF
H9 MN
HIV-1-Infected Cells
of HIV-1 MN, as well as of human antiserum to HIV-1, to
infected cells. Mouse MAbs 50.1, 59.1, 1026, and 1034 bound
with 3- to 15-fold-higher intensity to PM-1 cells infected with
T-CSF than to MT-CSF-infected cells, whereas the human
antiserum exhibited similar fluorescence intensities with both
infected cell lines (Fig. 2A).
We next evaluated human antibody recognition of the V3
region by testing the effect of V3 peptide competition on
human antibody binding to virus envelope expressed at the cell
surface. Staining of the surface of T-CSF-expressing cells was
markedly reduced by either the consensus V3 (identical to
MT-CSF V3 except for a Ser-to-Asn substitution at position
298) or MN V3 peptide (Fig. 2B). In contrast, antibody binding
to MT-CSF-infected cells was inhibited only partially by the
consensus V3 peptide and was not inhibited by the MN V3
peptide. HIV-1 RF and a control peptide showed minimal
effects on antibody binding to both isolates.
The low relative binding of monoclonal and polyclonal
antibodies to the V3 domain on the primary virus isolate
suggested that the MT and T-cell-tropic viruses may also differ
in sensitivity to antibody neutralization. The effects of antisera
from asymptomatic HIV-1-infected individuals were examined
in neutralization assays with infected cells or infectious cellfree supernatants. Six of seven human antisera at a 1:50
dilution completely inhibited the CPE of the fusion event
between T-CSF-infected and uninfected PM-1 cells (Fig. 3A).
In contrast, the same antisera inhibited the CPE of MT-CSFinfected cells by no more than 20 to 40%. Two of the antisera
were tested in twofold serial dilutions with cell-free virus (Fig.
3B). Both antisera significantly blocked the CPE of T-CSF
even at a 1:1600 dilution, whereas inhibition of the CPE of the
MT-CSF was apparent only at a 1:100 dilution. We also tested
MAbs 1026, 1034, and 50.1 in neutralization assays. All MAbs
inhibited the CPE of PM-1 cells infected with T-CSF as well as
of MN-infected H9 cells; however, none of the MAbs inhibited
syncytium formation and the subsequent CPE initiated by
PM-1 cells chronically infected with MT-CSF (Fig. 3C).
We also evaluated the susceptibility of T-CSF and MT-CSF
to neutralization by a polyclonal rabbit antiserum (PB69) to
recombinant gpl20 of the primary JR-CSF isolate, which is
identical in sequence to MT-CSF used in this study. The CPE
of T-CSF was almost completely inhibited by PB69 (1:50
dilution), whereas that of HIV-1 MN was inhibited by 70%
(Fig. 4B). In contrast, PB69 inhibited the CPE of MT-CSF by
only 10%.
A
50!:
1.
1.
.1
:
I
.1
11
50-
0-
II
E
C)
50 -
.
Background
MT-CSF.
-T-CSF. (-/
,
....I
IMAb 1026
\I
-.-
."I--rrr
-1.
DISCUSSION
In this report, we present a comparative analysis of an MT
virus and its T-cell-tropic variant. We have shown that the
transition from an MT type to a T-cell-tropic HIV-1 markedly
affects the immunological properties of the resultant variant
virus. The emergence of a T-cell-tropic variant correlated with
an increase in susceptibility to antibody neutralization relative
to the original isolate, a primary MT virus. Associated with this
phenotype transition, an increase in the exposure of immunodominant V3 sites occurred, with a resulting shift in the
antibody-resistant MT phenotype to an antibody-sensitive Tcell-tropic phenotype. On the basis of our results, we suggest
that MT isolates of HIV-1 are resistant to neutralizing antibodies as a consequence of low exposure of neutralizing
epitopes in the V3 domain.
Emergence of the T-cell-tropic JR-CSF variant was first
associated with an ability to continuously replicate in H9 cells
and to infect cell lines that are susceptible only to T-cell-tropic
strains of HIV-1. We detected four amino acid substitutions
(positions 298, 301, 304, and 315) and one insertion (between
positions 304 and 305) in the gpl20 V3 loop of T-CSF,
resulting in the addition of three positively charged residues.
I.
101
102
103
Fluorescence intensity
B
50-
.0-
E
=
a)
050
0)
MNV3
100
MT-CSF
T-CSF
50-
Background
Antiserum
Con V3
a)
.0
E
z
.41. :!== IIII.. ...........
-.
O|
I,
Im
50o -
RF V3
MN V3
0
RFV3
CD4 B
_A
0100
Fluorescence intensity
6009
_CD4 B
,-I
101
I,,I'rT------
102
-
103
,-A
104
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
50-
10°
To determine the contribution of V3-specific antibodies to
the neutralizing activity of human and rabbit antisera, we
incubated antisera with V3 loop peptides before the neutralization assay. Neutralization of T-CSF by human (Fig. 4A) or
rabbit (Fig. 4B) antisera was significantly inhibited in the
presence of either the consensus (MT) or the MN V3 peptide.
The quantitation of p24 antigen in culture supernatants from
syncytium formation assays showed comparable results (data
not shown).
To examine whether neutralizing antibodies would affect
virus selection when both phenotypes were present in the same
inoculum, we incubated both cell-free MT-CSF and T-CSF
supernatants (200 tissue culture infectious doses) with serum
from healthy control or HIV-1-infected individuals before
exposure to uninfected PM-1 cells. After 1 month in culture,
the V3 genotype and the phenotype of the resultant virus were
determined (Table 2). For virus supernatants incubated with
control antiserum, only T-CSF was subsequently detected in
the infected cells. For virus supernatants incubated with antiHIV-1 antiserum, only MT-CSF was detected in the chronically infected cultures.
1
......................
---,
50 -
'/.
I
:
Human
anti-HIV-I
antiserum
J. VIROL.
6010
BOU-HABIB ET AL.
A 100
Both tropism and replication rate are related to the structure
of the V3 domain (6, 8, 11, 12). Given that replacement of
negatively charged residues by positively charged amino acids
at only two positions in this domain is sufficient to produce
T-cell-tropic (or SI) variants (6, 8, 11-13), we suggest that the
mutations in the V3 sequence of T-CSF played a role in the
observed phenotype switch. Future studies with recombinant
viruses, substituting the V3 mutations back in the MT virus, are
required to verify this hypothesis.
Associated with the transition of the MT to the T-cell-tropic
.....
::. ...>-*phenotype, we detected changes in the exposure of V3 region
epitopes. Thus, the extent of binding of anti-V3 loop MAbs
was greater to PM-1 cells infected with T-CSF than to MT:
CSF-infected cells. Because MAb 59.1 recognizes a linear
:.........
epitope (GPGRAF) (43) common to both T-CSF and MTCSF, the difference in binding to cell surface envelope for this
MAb cannot be attributed to changes in the linear epitope
_
1:200
1:50
1:100
sequence. Similarly, the fine specificities of MAbs 1026 and
1034 indicate that both bind to the tip of the V3 loop; in
Antiserum Dilution
addition, they bind to recombinant (MT type) JR-CSF gpl20
as well as to the consensus V3 peptide (reference 29 and
unpublished results). Overall, these data support the hypothesis that the V3 region of the MT isolate either differs in
conformation from that of T-CSF or is cryptic (sterically
hidden), possibly because of loop interactions with other
o
regions of the envelope or with other cell surface molecules.
The binding of MAb 50.1, which recognizes the HIV-1 MN
epitope RIHIG (43) and, probably, the corresponding sequence in the T-CSF V3 domain (RIIHIG), may depend on
Q
both linear and conformational properties not present in the
_*
MT V3 loop. The high binding intensity of the MAbs to T-CSF
-0
..
that the conformations of the V3 loop are similar in
*
-..-.--.indicates
----::
both T-CSF and MN, probably as a result of similar contents or
_O
positions of positively charged residues. Indeed, both viruses
have positively charged residues at positions 301 (lysine) and
304 (arginine), and in addition, lysine is present at position 316
l
l
_
1:800
1:1600
in T-CSF and position 317 in MN.
1:400
1:200
1:100
The ability of V3 peptides to block the binding of human
Antiserum Dilution
polyclonal anti-HIV-1 antibodies to cells infected with T-CSF,
but not to MT-CSF-infected cells, is consistent with the MAb
H9 MN
MT-CSF
T-CSF
data and also indicates that the V3 domain of T-CSF is
T
exposed and is the major target for polyclonal antibodies. The
T
l
)
MT V3 domain is less accessible to polyclonal antibodies and
makes a minor contribution to total antibody binding. The
weak but detectable binding of anti-V3 antibodies to MT-CSF
indicates that a minor fraction of the V3 sites is accessible to
antibodies, thus suggesting that the MT-V3 site may be
conformationally flexible but skewed toward an inaccessible
_
~~~~~~~~~~~conformation.
_
80
1-1
w
a0
60
0
0
~-D
40
C
20
B 100
80
w
a0
0
.0
60
40
-
20
0
C
10C
8C
I-
0
I.-C
60
C.0
0
.0
C0
I-I
I
I
40
20
0
MAb 50.1
MAb 1034
MAb 1026
FIG. 3. Abilities of antisera from HIV-1-infected individuals and
mouse anti-V3 MAbs to neutralize MT-CSF and T-CSF HIV-1
isolates. (A) PM-1 cells infected with MT-CSF or T-CSF (104 per well)
were incubated with human antiserum to HIV-1 at various dilutions
before the addition of uninfected PM-1 cells (5 x 104 per well). The
CPE was evaluated after 72 h, and percent inhibition of CPE was
calculated. Data are from a representative experiment. Each symbol
represents one of seven antisera tested. Solid lines, T-CSF; dotted
lines, MT-CSF. Control normal human serum had no significant
inhibitory effect (data not shown). (B) Infectious cell-free supernatants
were incubated with human antiserum to HIV-1 at various dilutions
before the addition of uninfected PM-1 cells (2 x 104 per well). CPE
was measured after 6 to 7 days of incubation. Data are from a
representative experiment, with each symbol representing one of two
antisera tested. Solid lines, T-CSF; dotted lines, MT-CSF. Control
normal human serum did not produce significant inhibition (data not
shown). (C) PM-1 cells infected with MT-CSF or T-CSF were incubated with MAb 1026 (5 ,ug/ml), 1034 (10 ju.g/ml), or 50.1 (10 ptg/ml)
before addition of uninfected PM-1 cells and determination of CPE as
described for panel A. Data are means ± standard errors from a
representative experiment. The effects of the MAbs on the CPE of
MN-infected H9 cells are shown for comparison. A control MAb to the
C4 region of HIV-1 strain IIIB had no significant inhibitory effects at
10 ,ug/ml (data not shown).
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
0
........
CRYPTIC V3 REGION PROTECTS HIV-1 FROM NEUTRALIZATION
VOL. 68, 1994
100
m
T-CSF
H9MN
6011
MT-CSF
80
0
aLU
0X
CL
60
cJ
0
.0
40
._
20
+ConV3
+MNV3
+CD4B
Human antiserum
+ConV3
+MNV3
+CD4B
Rabbit PB69 antiserum
FIG. 4. Effect of prior incubation of antiserum with V3 loop peptides on neutralization of MT-CSF and T-CSF isolates. Human antiserum to
HIV-1 (1:200 dilution) or rabbit antiserum PB69 (1:50 dilution) was incubated with the HIV-1 consensus (Con) or MN V3 loop peptide or the
control CD4B peptide at a concentration of 10 p.g/ml. Peptide-treated antisera were then incubated with PM-1 cells infected with MT-CSF or
T-CSF or H9 cells infected with MN. After subsequent addition of uninfected PM-1 cells, the CPE was evaluated. Values are means ± standard
errors of four (A) or three (B) experiments. Control, normal human, or rabbit sera did not produce significant inhibition of CPE (data not shown).
Neutralization assays with polyclonal human and rabbit
antisera and anti-V3 MAbs revealed that T-CSF was sensitive
and MT-CSF was resistant to blocking antibodies. The target
for neutralizing activity of the polyclonal antisera toward
T-CSF was shown to be the V3 domain, as demonstrated by
inhibition of neutralization after prior incubation of antisera
with HIV-1 consensus or MN V3 peptides. One explanation
for MT-CSF resistance is that a major fraction of envelope on
the surface of the MT-CSF-infected cells is not bound by
anti-V3 antibodies and thus is free to mediate cell-to-cell
fusion. It has been reported that a human MAb (447-52-D) was
able to neutralize the MT isolate SF-162, although less efficiently than eight other lymphotropic HIV-1 isolates (16).
Because of the use of different methods, it is difficult to directly
compare that finding with those presented in this report, but it
is possible that the SF-162 V3 loop is more exposed to
antibodies than is the V3 domain of the JR-CSF strain. Other
envelope epitopes, outside the V3 domain, may contribute to
neutralizing activity (5, 14, 25, 42), as shown by the low level of
TABLE 2. V3 genotype and phenotype of HIV-1 JR-CSF
recovered after infection of PM-1 cells with MT-CSF and
T-CSF isolates that had been incubated in the presence
of serum from control or HIV-1-infected individualsa
Genotype/phenotype
Inoculum
MT-CSF
T-CSF
MT + T-CSF
serum
Anti-HIV-1
antiserum
MT/MT
T/T
T/T
MT/MT
-/MT/MT
Control
a MT-CSF, T-CSF, or a mixture of both viruses was incubated for 1 h with
serum from control or HIV-1-infected individuals (1:50 dilution) and then used
to infect PM-1 cells. After 1 month in culture, the V3 genotype was determined
by PCR amplification and direct sequencing of the V3 region, and phenotypes of
harbored viruses were analyzed. T, T-cell tropic.
neutralization to both MT and T-cell-tropic viruses after
treatment of antisera with V3 peptides.
The neutralization results with the rabbit antiserum prepared against recombinant gpl20 of the primary JR-CSF virus
indicate that the MT V3 loop, despite its poor exposure on the
membrane form of the envelope proteins, is able, either in the
native form of gpl20 or after processing, to elicit neutralizing
antibodies. These antibodies recognize and block the T-celltropic virus, but they neutralize only weakly the MT isolate,
against which they were raised. The potent V3-specific neutralizing activity of human antisera against T-CSF suggests
either that the V3 epitopes on MT viruses are immunogenic or
that infected individuals harbor T-cell-tropic variants that
induce anti-V3 reactivity. The data obtained with the rabbit
antiserum to MT-CSF gpl20 are consistent with the view that
MT viruses may serve as an early driving force in the course of
HIV infection in stimulating neutralizing antibodies to the MT
V3 domain, which cross-react with the T-cell-tropic V3 site.
Resistance of the MT virus to antibodies generated against the
MT envelope suggests that vaccines based on primary or MT
envelopes as the antigen may not provide any more activity
than do vaccines based on T-cell-tropic envelopes.
Antibodies to the V3 loop are prevalent in HIV-1-infected
individuals (19), and it is reasonable to assume that they can
offer protection against T-cell-tropic variants. On the basis of
our observation that a human neutralizing antiserum completely blocked the infectivity of T-CSF, but not that of
MT-CSF, when both phenotypes were present in the same
inoculum, we predict that anti-V3 antibodies may not prevent
HIV-1 infection and dissemination if the harbored virus is
present in the primary/MT form. MT virus phenotypes are
most prevalent in asymptomatic infected individuals (17, 3335, 39) and are the most frequently transmitted form of HIV-1
in vivo (45). It is possible that sensitive T-cell-tropic variants
are blocked by antibodies during the asymptomatic period of
the disease, which could result in low transmission of this
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
0
6012
BOU-HABIB ET AL.
phenotype and reduced immunopathogenesis mediated by
T-cell-tropic strains. However, the persistent replication of MT
viruses, together with continuous development of variants
resistant to autologous antibodies (1, 2, 24, 40, 41), would
result in progressive immune damage, further depletion of
neutralizing antibodies and cell-mediated responses, and eventually the emergence of more aggressive viruses that initiate
progression to AIDS.
Our results help to explain the marked resistance of primary/MT virus isolates to antibody neutralization mediated by
hyperimmune sera from HIV-1-infected individuals and vaccinees (9). They further illustrate that a major obstacle to
vaccine effectiveness may be the cryptic nature of neutralization epitopes in the virus phenotype predominantly transmit-
J. VIROL.
12.
13.
14.
15.
ACKNOWLEDGMENTS
We acknowledge Neil Goldman for critical review of the manuscript
and Howard Mostoswki for the flow microfluorimetry analysis.
Completion of this work was supported in part by funds from the
FDA Office of Women's Health and the NIH AIDS Targeted Antiviral
16.
Program.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
REFERENCES
Albert, J., B. Abrahamsson, K. Nagy, E. Aurelius, H. Gaines, G.
Nystrom, and E. M. Fenyo. 1990. Rapid development of isolatespecific neutralizing antibodies after primary HIV-1 infection and
consequent emergence of virus variants which resist neutralization
by autologous sera. AIDS 4:107-112.
Arendrup, M., C. Nielsen, J. E. Hansen, C. Pedersen, L.
Mathiesen, and J. 0. Nielsen. 1992. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus
and subsequent development of escape virus neutralizing antibodies. J. Acquired Immune Defic. Syndr. 5:303-307.
Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S.
Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun,
C. Rouzioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation
of a T-lymphotropic retrovirus from a patient at risk for acquired
immune deficiency syndrome (AIDS). Science 220:868-871.
Boyd, M. T., G. R. Simpson, A. J. Cann, M. A. Johnson, and R. A.
Weiss. 1993. A single amino acid substitution in the Vl loop of
human immunodeficiency virus type 1 gpl20 alters cellular tropism. J. Virol. 67:3649-3652.
Broliden, P. A., A. Von Gegerfelt, P. Clapham, J. Rosen, E. M.
Fenyo, B. Wahren, and K. Broliden. 1992. Identification of human
neutralization-inducing regions of the human immunodeficiency
virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA
89:461-465.
Cann, A. J., M. J. Churcher, M. Boyd, W. O'Brien, J. Q. Zhao, J.
Zack, and I. S. Chen. 1992. The region of the envelope gene of
human immunodeficiency virus type 1 responsible for determination of cell tropism. J. Virol. 66:305-309.
Cann, A. J., J. A. Zack, A. S. Go, S. J. Arrigo, Y. Koyanagi, P. L.
Green, S. Pang, and I. S. Chen. 1990. Human immunodeficiency
virus type 1 T-cell tropism is determined by events prior to
provirus formation. J. Virol. 64:4735-4742.
Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. 1992.
Macrophage-tropic human immunodeficiency virus isolates from
different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical
amino acids involved in cell tropism. J. Virol. 66:6547-6554.
Cohen, J. 1993. Jitters jeopardize AIDS vaccine trials. Science
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
262:980-981.
Daar, E. S.,
X. L. Li, T. Moudgil, and D. D. Ho. 1990. High
concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
Proc. Natl. Acad. Sci. USA 87:6574-6578.
11. De Jong, J. J., A. De Ronde, W. Keulen, M. Tersmette, and J.
Goudsmit. 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-
28.
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
ted in vivo.
inducing phenotype: analysis by single amino acid substitution. J.
Virol. 66:6777-6780.
De Jong, J. J., J. Goudsmit, W. Keulen, B. Klaver, W. Krone, M.
Tersmette, and A. De Ronde. 1992. Human immunodeficiency
virus type 1 clones chimeric for the envelope V3 domain differ in
syncytium formation and replication capacity. J. Virol. 66:757-765.
Fouchier, R. A., M. Groenink, N. A. Kootstra, M. Tersmette, H. G.
Huisman, F. Miedema, and H. Schuitemaker. 1992. Phenotypeassociated sequence variation in the third variable domain of the
human immunodeficiency virus type 1 gpl20 molecule. J. Virol.
66:3183-3187.
Fung, M. S., C. R. Sun, W. L. Gordon, R. S. Liou, T. W. Chang,
W. N. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and
characterization of a neutralization site within the second variable
region of human immunodeficiency virus type 1 gpl20. J. Virol.
66:848-856.
Gallo, R. C., S. Z. Salahuddin, M. Popovic, G. M. Shearer, M.
Kaplan, B. F. Haynes, T. J. Palker, R. Redfield, J. Oleske, and B.
Safai. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.
Science 224:500-503.
Gorny, M., A. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E.
Emini, S. Koenig, and S. Zolla-Pazner. 1994. Neutralization of
diverse human immunodeficiency virus type 1 variants by an
anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
Gruters, R. A., F. G. Terpstra, R. E. De Goede, J. W. Mulder, F. de
Wolf, P. T. Schellekens, R. A. Van Lier, M. Tersmette, and F.
Miedema. 1991. Immunological and virological markers in individuals progressing from seroconversion to AIDS. AIDS 5:837844.
Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of
HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and
application in a plaque assay. Science 229:563-566.
Holmback, K., P. Kusk, E. F. Hulgaard, T. H. Bugge, E. Scheibel,
and B. 0. Lindhardt. 1993. Autologous antibody response against
the principal neutralizing domain of human immunodeficiency
virus type 1 isolated from infected humans. J. Virol. 67:1612-1619.
Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991.
Identification of the envelope V3 loop as the primary determinant
of cell tropism in HIV-1. Science 253:71-74.
Kliks, S. C., T. Shioda, N. L. Haigwood, and J. A. Levy. 1993. V3
variability can influence the ability of an antibody to neutralize or
enhance infection by diverse strains of human immunodeficiency
virus type 1. Proc. Natl. Acad. Sci. USA 90:11518-11522.
Koot, M., A. H. Vos, R. P. Keet, R. E. De Goede, M. W. Dercksen,
F. G. Terpstra, R. A. Coutinho, F. Miedema, and M. Tersmette.
1992. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6:49-54.
Lusso, P., et al. Unpublished data.
Montefiori, D. C., I. Y. Zhou, B. Barnes, D. Lake, E. M. Hersh, Y.
Masuho, and L. B. Lefkowitz, Jr. 1991. Homotypic antibody
responses to fresh clinical isolates of human immunodeficiency
virus. Virology 182:635-643.
Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or
conformationally sensitive epitopes on the gpl20 glycoprotein of
human immunodeficiency virus type 1 are highly prevalent in sera
of infected humans. J. Virol. 67:863-875.
Moore, J. P., J. A. McKeating, Y. X. Huang, A. Ashkenazi, and
D. D. Ho. 1992. Virions of primary human immunodeficiency virus
type 1 isolates resistant to soluble CD4 (sCD4) neutralization
differ in sCD4 binding and glycoprotein gpl20 retention from
sCD4-sensitive isolates. J. Virol. 66:235-243.
Myers, G., J. A. Berzofsky, B. Korber, R. F. Smith, and G. N.
Pavlakis. 1992. Human retrovirus and AIDS. A compilation and
analysis of nucleic acid and amino acid sequences. Theoretical
Biology and Biophysics, Los Alamos National Laboratory, Los
Alamos, N. Mex.
Nakamura, G. R., R. Byrn, K. Rosenthal, J. P. Porter, M. R.
Hobbs, L. Riddle, D. J. Eastman, D. Dowbenko, T. Gregory, and
B. M. Fendly. 1992. Monoclonal antibodies to the extracellular
domain of HIV-1IIIB gpl60 that neutralize infectivity, block
binding to CD4, and react with diverse isolates. AIDS Res. Hum.
Retroviruses 8:1875-1885.
VOL. 68, 1994
CRYPTIC V3 REGION PROTECTS HIV-1 FROM NEUTRALIZATION
37. Shaw, G. M., B. H. Hahn, S. K. Arya, J. E. Groopman, R. C. Gallo,
and F. Wong-Staal. 1984. Molecular characterization of human
T-cell leukemia (lymphotropic) virus type III in the acquired
immune deficiency syndrome. Science 226:1165-1171.
38. Smith, S. D., M. Shatsky, P. S. Cohen, R. Warnke, M. P. Link, and
B. E. Glader. 1984. Monoclonal antibody and enzymatic profiles of
human malignant T-lymphoid cells and derived cell lines. Cancer
Res. 44:5657-5660.
39. Tersmette, M., R. A. Gruters, F. de Wolf, R. E. De Goede, J. M.
Lange, P. T. Schellekens, J. Goudsmit, H. G. Huisman, and F.
Miedema. 1989. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired
immunodeficiency syndrome: studies on sequential HIV isolates.
J. Virol. 63:2118-2125.
40. Tremblay, M., and M. A. Wainberg. 1990. Neutralization of
multiple HIV-1 isolates from a single subject by autologous
sequential sera. J. Infect. Dis. 162:735-737.
41. Von Gegerfelt, A., J. Albert, L. Morfeldt-Manson, K. Broliden, and
E. M. Fenyo. 1991. Isolate-specific neutralizing antibodies in
patients with progressive HIV-1-related disease. Virology 185:
162-168.
42. Warren, R. Q., S. A. Anderson, W. M. Nkya, J. F. Shao, C. W.
Hendrix, G. P. Melcher, R. R. Redfield, and R. C. Kennedy. 1992.
Examination of sera from human immunodeficiency virus type 1
(HIV-1)-infected individuals for antibodies reactive with peptides
corresponding to the principal neutralizing determinant of HIV-1
gpl20 and for in vitro neutralizing activity. J. Virol. 66:5210-5215.
43. White-Scharf, M. E., B. J. Potts, L. M. Smith, K. A. Sokolowski,
J. R. Rusche, and S. Silver. 1993. Broadly neutralizing monoclonal
antibodies to the V3 region of HIV-1 can be elicited by peptide
immunization. Virology 192:197-206.
44. Wolfs, T. F., P. L. Nara, and J. Goudsmit. 1993. Genotypic and
phenotypic variation of HIV-1: impact on AIDS pathogenesis and
vaccination. Chem. Immunol. 56:1-33.
45. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D.
Ho. 1993. Genotypic and phenotypic characterization of HIV-1
patients with primary infection. Science 261:1179-1181.
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
29. Nakamura, G. R., R. Byrn, D. M. Wilkes, J. A. Fox, M. R. Hobbs,
R. Hastings, H. C. Wessling, M. A. Norcross, B. M. Fendly, and
P. W. Berman. 1993. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of
gpl20 from human immunodeficiency virus type 1. J. Virol.
67:6179-6191.
30. O'Brien, W. A., I. S. Chen, D. D. Ho, and E. S. Daar. 1992.
Mapping genetic determinants for human immunodeficiency virus
type 1 resistance to soluble CD4. J. Virol. 66:3125-3130.
31. Oravecz, T., and M. A. Norcross. 1993. Costimulatory properties
of the human CD4 molecule: enhancement of CD3-induced T cell
activation by human immunodeficiency virus type I through viral
envelope glycoprotein gpl20. AIDS Res. Hum. Retroviruses
9:945-955.
32. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984.
Detection, isolation, and continuous production of cytopathic
retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.
Science 224:497-500.
33. Roos, M. T., J. M. Lange, R. E. De Goede, R. A. Coutinho, P. T.
Schellekens, F. Miedema, and M. Tersmette. 1992. Viral phenotype and immune response in primary human immunodeficiency
virus type 1 infection. J. Infect. Dis. 165:427-432.
34. Schellekens, P. T., M. Tersmette, M. T. Roos, R. P. Keet, F. de
Wolf, R. A. Coutinho, and F. Miedema. 1992. Biphasic rate of
CD4+ cell count decline during progression to AIDS correlates
with HIV-1 phenotype. AIDS 6:665-669.
35. Schuitemaker, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E.
De Goede, R. P. van Steenwijk, J. M. Lange, J. K. Schattenkerk, F.
Miedema, and M. Tersmette. 1992. Biological phenotype of
human immunodeficiency virus type 1 clones at different stages of
infection: progression of disease is associated with a shift from
monocytotropic to T-cell-tropic virus population. J. Virol. 66:
1354-1360.
36. Scudiero, D. A., R. H. Shoemaker, K. D. Paull, A. Monks, S.
Tierney, T. H. Nofziger, M. J. Currens, D. Seniff, and M. R. Boyd.
1988. Evaluation of a soluble tetrazolium/formazan assay for cell
growth and drug sensitivity in culture using human and other
tumor cell lines. Cancer Res. 48:4827-4833.
6013